Breaking News Instant updates and real-time market news.

AANNF

Aroundtown

$3.56 /

+ (+0.00%)

12:48
07/05/22
07/05
12:48
07/05/22
12:48

Aroundtown price target lowered to EUR 4.10 from EUR 4.50 at Barclays

Barclays analyst Paul May lowered the firm's price target on Aroundtown to EUR 4.10 from EUR 4.50 and keeps an Underweight rating on the shares.

OTHER BREAKING NEWS FROM THE FLY

General news
Market Update: » 02:40
08/12/22
08/12
02:40
08/12/22
02:40
$ECON

Economic Data

/

+

Market Update: Stocks in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

$ECON Economic Data
/

+

Recommendations
Apyx Medical price target raised to $12 from $6 at Piper Sandler » 20:54
08/11/22
08/11
20:54
08/11/22
20:54
APYX

Apyx Medical

$10.34 /

-0.51 (-4.70%)

Piper Sandler analyst…

Piper Sandler analyst Matt O'Brien raised the firm's price target on Apyx Medical to $12 from $6 and keeps an Overweight rating on the shares. The company's Q2 revenue missed expectations due to greater-than-expected demand impacts within the Advanced Energy business from the FDA safety communication in March, though next year is setting up for an acceleration in the business, with mid-teens growth expected through FY25, the analyst tells investors in a research note.

ShowHide Related Items >><<
APYX Apyx Medical
$10.34 /

-0.51 (-4.70%)

APYX Apyx Medical
$10.34 /

-0.51 (-4.70%)

07/19/22 Lake Street
Apyx Medical price target raised to $17 from $14 at Lake Street
07/18/22 Piper Sandler
Apyx Medical FDA clearance should help reaccelerate growth, says Piper Sandler
07/11/22 Lake Street
Apyx Medical price target raised to $14 from $12 at Lake Street
05/26/22 Piper Sandler
Piper says Apyx Medical label expansion 'positive on a couple of levels'
APYX Apyx Medical
$10.34 /

-0.51 (-4.70%)

Recommendations
Sight Sciences price target lowered to $15 from $17 at Piper Sandler » 20:46
08/11/22
08/11
20:46
08/11/22
20:46
SGHT

Sight Sciences

$9.84 /

-0.29 (-2.86%)

Piper Sandler analyst…

Piper Sandler analyst Matt O'Brien lowered the firm's price target on Sight Sciences to $15 from $17 after its Q2 earnings miss as he adjusts his valuation model with unchanged 6-times enterprise value to expected FY23 sales multiple but keeps an Overweight rating on the shares. The analyst still believes that Sight Sciences management is building a strong franchise that will generate sizable levels of sales and eventually profitability.

ShowHide Related Items >><<
SGHT Sight Sciences
$9.84 /

-0.29 (-2.86%)

SGHT Sight Sciences
$9.84 /

-0.29 (-2.86%)

07/25/22 Stifel
Sight Sciences initiated with a Hold at Stifel
05/11/22 Piper Sandler
Sight Sciences price target lowered to $17 from $23 at Piper Sandler
04/19/22 Piper Sandler
Piper Sandler continues to recommend exposure to medtech space after J&J results
03/25/22 Citi
Sight Sciences price target lowered to $35 from $39 at Citi
SGHT Sight Sciences
$9.84 /

-0.29 (-2.86%)

SGHT Sight Sciences
$9.84 /

-0.29 (-2.86%)

SGHT Sight Sciences
$9.84 /

-0.29 (-2.86%)

Earnings
ProFrac Holding reports Q2 adjusted EBITDA $210.6M vs. $34.1M last year » 20:28
08/11/22
08/11
20:28
08/11/22
20:28
PFHC

ProFrac Holding

$18.24 /

+0.44 (+2.47%)

Reports Q2 revenue…

Reports Q2 revenue $589.8M, consensus $569.4M. The company states: "The Company is deploying its first electric fleet during the third quarter and expects to average approximately 31 active fleets for the full quarter. We expect to deploy two more electric fleets in the fourth quarter. There are no current plans to reactivate any conventional or dual fuel fleets for the remainder of 2022. The Company also expects incremental improvement in third quarter results, as compared to the second quarter attributable to further bundling of materials with our pressure pumping services, continued pricing improvements, and the anticipated deployment of our first electric fleet."

ShowHide Related Items >><<
PFHC ProFrac Holding
$18.24 /

+0.44 (+2.47%)

PFHC ProFrac Holding
$18.24 /

+0.44 (+2.47%)

07/15/22 BofA
ProFrac Holding downgraded to Neutral from Buy at BofA
07/13/22 Morgan Stanley
ProFrac Holding price target lowered to $28 from $30 at Morgan Stanley
06/22/22 Johnson Rice
ProFrac Holding initiated with a Buy at Johnson Rice
06/21/22 Stifel
ProFrac Holding price target raised to $27 from $24 at Stifel
  • 13
    May
PFHC ProFrac Holding
$18.24 /

+0.44 (+2.47%)

PFHC ProFrac Holding
$18.24 /

+0.44 (+2.47%)

Hot Stocks
Offerpad Solutions director buys $1.69M in common stock » 20:13
08/11/22
08/11
20:13
08/11/22
20:13
OPAD

Offerpad Solutions

$1.70 /

-0.005 (-0.29%)

In a regulatory filing,…

In a regulatory filing, Offerpad Solutions disclosed that its director Roberto Sella bought 1M shares of common stock on August 9th in a total transaction size of $1.69M.

ShowHide Related Items >><<
OPAD Offerpad Solutions
$1.70 /

-0.005 (-0.29%)

OPAD Offerpad Solutions
$1.70 /

-0.005 (-0.29%)

08/04/22 Cantor Fitzgerald
Offerpad Solutions price target lowered to $5 from $10 at Cantor Fitzgerald
07/22/22 Cantor Fitzgerald
Offerpad Solutions assumed with an Overweight at Cantor Fitzgerald
07/11/22 Wedbush
Offerpad Solutions initiated with an Outperform at Wedbush
07/11/22 Wedbush
Offerpad Solutions initiated with an Outperform at Wedbush
OPAD Offerpad Solutions
$1.70 /

-0.005 (-0.29%)

OPAD Offerpad Solutions
$1.70 /

-0.005 (-0.29%)

OPAD Offerpad Solutions
$1.70 /

-0.005 (-0.29%)

OPAD Offerpad Solutions
$1.70 /

-0.005 (-0.29%)

Hot Stocks
Cathie Wood's ARK Investment bought 628K shares of Fate Therapeutics today  20:10
08/11/22
08/11
20:10
08/11/22
20:10
FATE

Fate Therapeutics

$32.68 /

+0.26 (+0.80%)

 
ShowHide Related Items >><<
FATE Fate Therapeutics
$32.68 /

+0.26 (+0.80%)

FATE Fate Therapeutics
$32.68 /

+0.26 (+0.80%)

08/04/22 Oppenheimer
Fate Therapeutics price target lowered to $90 from $135 at Oppenheimer
07/28/22 Needham
Fate Therapeutics initiated with a Hold at Needham
07/11/22 BMO Capital
Fate Therapeutics upgraded to Outperform from Market Perform at BMO Capital
06/03/22 Baird
Baird starts Fate Therapeutics at Neutral with limited data on NK cell therapies
FATE Fate Therapeutics
$32.68 /

+0.26 (+0.80%)

FATE Fate Therapeutics
$32.68 /

+0.26 (+0.80%)

Hot Stocks
Cathie Wood's ARK Investment bought 101K shares of Teladoc today  20:09
08/11/22
08/11
20:09
08/11/22
20:09
TDOC

Teladoc

$37.98 /

+0.21 (+0.56%)

 
ShowHide Related Items >><<
TDOC Teladoc
$37.98 /

+0.21 (+0.56%)

TDOC Teladoc
$37.98 /

+0.21 (+0.56%)

08/11/22 DA Davidson
Teladoc initiated with a Buy at DA Davidson
08/02/22 Berenberg
Berenberg downgrades Teladoc to Hold on 'underwhelming execution'
08/02/22 Cowen
Teladoc downgraded to Market Perform from Outperform at Cowen
07/29/22 Deutsche Bank
Teladoc price target lowered to $34 from $44 at Deutsche Bank
TDOC Teladoc
$37.98 /

+0.21 (+0.56%)

TDOC Teladoc
$37.98 /

+0.21 (+0.56%)

TDOC Teladoc
$37.98 /

+0.21 (+0.56%)

TDOC Teladoc
$37.98 /

+0.21 (+0.56%)

Syndicate
Corphousing prices 3.375M share IPO at $4.00 » 20:02
08/11/22
08/11
20:02
08/11/22
20:02
CHG

Corphousing

/

+

Maxim Group LLC is acting…

Maxim Group LLC is acting as the lead book-running manager in connection with the offering and Joseph Gunnar & Co. is acting as joint book-running manager for the offering.

ShowHide Related Items >><<
  • 12
    Aug
Syndicate
Portillo's 8M share Secondary priced at $23.75 » 19:57
08/11/22
08/11
19:57
08/11/22
19:57
PTLO

Portillo's

$25.02 /

-0.985 (-3.79%)

The deal priced below…

The deal priced below last closing price of $24.97. Jefferies and Morgan Stanley are acting as joint book running managers for the offering.

ShowHide Related Items >><<
PTLO Portillo's
$25.02 /

-0.985 (-3.79%)

PTLO Portillo's
$25.02 /

-0.985 (-3.79%)

08/05/22 Baird
Portillo's price target raised to $30 from $22 at Baird
08/05/22 Piper Sandler
Portillo's price target raised to $27 from $23 at Piper Sandler
06/28/22 Morgan Stanley
Portillo's initiated with an Equal Weight at Morgan Stanley
06/08/22
Baird to hold a conference
PTLO Portillo's
$25.02 /

-0.985 (-3.79%)

  • 12
    Aug
  • 21
    Oct
PTLO Portillo's
$25.02 /

-0.985 (-3.79%)

PTLO Portillo's
$25.02 /

-0.985 (-3.79%)

Syndicate
Reborn Coffee 1.44M share IPO priced at $5.00 » 19:49
08/11/22
08/11
19:49
08/11/22
19:49
REBN

Reborn Coffee

/

+

The deal size was…

The deal size was increased to $7.2M from $6.0M. EF Hutton is acting as sole book running manager for the offering.

ShowHide Related Items >><<
  • 12
    Aug
REBN Reborn Coffee
/

+

General news
Fed President Mary Daly says workers looking for jobs now do not see recession » 19:46
08/11/22
08/11
19:46
08/11/22
19:46
SPY

SPDR S&P 500 ETF Trust

$420.01 /

+0.06 (+0.01%)

, SPX

S&P 500

/

+

, QQQ

Invesco QQQ Trust

$324.08 /

-1.84 (-0.56%)

Says long way from…

Says long way from evaluating risks of not pulling back on tightening; Says the main risk in the economy is that inflation is too high; Says another tightening of 50bps makes sense to me right now, but have open mind on 75bps hike in September. Says looking at job openings and quit rate in addition to unemployment rate; Says will take some time for home rental inflation to level off; Says if services inflation continues to rise, we still have a lot of work to do; Says about 100bps increase before the end of 2022 looks right for now; Says will raise rates to a level appropriate and then hold them there for a while. Comments from Bloomberg TV interview.

ShowHide Related Items >><<
SPY SPDR S&P 500 ETF Trust
$420.01 /

+0.06 (+0.01%)

QQQ Invesco QQQ Trust
$324.08 /

-1.84 (-0.56%)

SPY SPDR S&P 500 ETF Trust
$420.01 /

+0.06 (+0.01%)

07/25/22 JPMorgan
JPMorgan strategist says mild recession already priced in
07/13/22 Nomura
Nomura expects 100 point rate hike in July after June CPI data
07/01/22 JPMorgan
JPMorgan forecast 'perilously close' to recession after GDP cuts
06/27/22 Citi
Citi cuts S&P 500 year-end target, sees positive second half setup
SPX S&P 500
/

+

QQQ Invesco QQQ Trust
$324.08 /

-1.84 (-0.56%)

04/25/22 Gordon Haskett
Twitter bid more attractive after market selloff, says Gordon Haskett
SPY SPDR S&P 500 ETF Trust
$420.01 /

+0.06 (+0.01%)

SPY SPDR S&P 500 ETF Trust
$420.01 /

+0.06 (+0.01%)

SPY SPDR S&P 500 ETF Trust
$420.01 /

+0.06 (+0.01%)

QQQ Invesco QQQ Trust
$324.08 /

-1.84 (-0.56%)

SPX S&P 500
/

+

SPY SPDR S&P 500 ETF Trust
$420.01 /

+0.06 (+0.01%)

SPX S&P 500
/

+

QQQ Invesco QQQ Trust
$324.08 /

-1.84 (-0.56%)

Earnings
4D Molecular reports Q2 EPS (87c), consensus (85c) » 19:06
08/11/22
08/11
19:06
08/11/22
19:06
FDMT

4D Molecular

$10.37 /

-0.27 (-2.54%)

"Maintaining our…

"Maintaining our momentum from the first quarter, we continued to execute towards our clinical and corporate milestones, including progress across all of our five clinical-stage product candidates," said David Kirn, M.D., Co-founder, President and Chief Executive Officer of 4DMT. "In addition, the protocol amendment for the 4D-310 Phase 1/2 clinical trial in Fabry disease will expand access to include female patients, a large and significantly affected patient population with Fabry disease. We have maintained our focus on efficient cash utilization, with current cash available to support our operations into the first half of 2025. Our team is committed to relentless execution as we make progress toward key clinical data readouts in the first half of 2023 and beyond."

ShowHide Related Items >><<
FDMT 4D Molecular
$10.37 /

-0.27 (-2.54%)

FDMT 4D Molecular
$10.37 /

-0.27 (-2.54%)

06/22/22 Jefferies
4D Molecular initiated with a Buy at Jefferies
06/13/22 Wedbush
Sangamo assumed with a Neutral, $5 price target at Wedbush
01/04/22 SVB Securities
SVB Leerink bullish on 4D Molecular, initiates with an Outperform
01/04/22 SVB Securities
4D Molecular initiated with an Outperform at SVB Leerink
FDMT 4D Molecular
$10.37 /

-0.27 (-2.54%)

  • 29
    Oct
FDMT 4D Molecular
$10.37 /

-0.27 (-2.54%)

Earnings
PureCycle Technologies reports Q2 EPS (9c), consensus (14c) » 19:04
08/11/22
08/11
19:04
08/11/22
19:04
PCT

PureCycle Technologies

$9.47 /

+0.215 (+2.32%)

The company states:…

The company states: "To date, we have not generated any operating revenue. We expect to begin to generate revenue in 2023 from our commercial plant and PreP facilities."

ShowHide Related Items >><<
PCT PureCycle Technologies
$9.47 /

+0.215 (+2.32%)

PCT PureCycle Technologies
$9.47 /

+0.215 (+2.32%)

03/10/22 Craig-Hallum
PureCycle Technologies price target lowered to $18 from $26 at Craig-Hallum
03/10/22 Oppenheimer
PureCycle Technologies price target lowered to $16 from $28 at Oppenheimer
11/12/21 Craig-Hallum
PureCycle Technologies price target lowered to $26 from $48 at Craig-Hallum
09/23/21 Cowen
PureCycle Technologies initiated with an Outperform at Cowen
PCT PureCycle Technologies
$9.47 /

+0.215 (+2.32%)

PCT PureCycle Technologies
$9.47 /

+0.215 (+2.32%)

Earnings
Kinnate Biopharma reports Q2 EPS (62c), consensus (64c) » 18:59
08/11/22
08/11
18:59
08/11/22
18:59
KNTE

Kinnate Biopharma

$13.33 /

-1.47 (-9.93%)

"Kinnate is making…

"Kinnate is making meaningful progress with its proprietary clinical and preclinical precision oncology programs," said Nima Farzan, chief executive officer, Kinnate Biopharma Inc. "We continue to expand the global footprint of clinical trial sites for our pan-RAF inhibitor, KIN-2787, for which we expect to share initial clinical data later this year. The Kinnate Discovery Engine is actively generating new research leads, and with our financial strength, we're well positioned to invest in breakthrough science and long-term growth of the company."

ShowHide Related Items >><<
KNTE Kinnate Biopharma
$13.33 /

-1.47 (-9.93%)

KNTE Kinnate Biopharma
$13.33 /

-1.47 (-9.93%)

07/28/22 H.C. Wainwright
Kinnate Biopharma initiated with a Buy at H.C. Wainwright
06/03/22 Wedbush
Wedbush downgrades Turning Point, says deal positive for small/mid-cap biotechs
05/18/22 Piper Sandler
Kinnate Biopharma price target lowered to $30 from $52 at Piper Sandler
01/07/22 Wedbush
Kinnate Biopharma price target lowered to $44 from $53 at Wedbush
KNTE Kinnate Biopharma
$13.33 /

-1.47 (-9.93%)

Syndicate
Silence Therapeutics prices 5.95M ADSs at $9.50 per share » 18:58
08/11/22
08/11
18:58
08/11/22
18:58
SLN

Silence Therapeutics

$9.95 /

+0.075 (+0.76%)

Silence intends to use…

Silence intends to use the net proceeds of the offering, together with its existing cash and cash equivalents to fund the advancement of its clinical trials, including its Phase 2 trial of SLN360 in ASCVD and its Phase 1/2 trial of SLN124 in polycythemia vera, as well as expansion of pipeline programs, working capital and general corporate purposes. Morgan Stanley and William Blair are acting as joint book-running managers for the offering.

ShowHide Related Items >><<
SLN Silence Therapeutics
$9.95 /

+0.075 (+0.76%)

SLN Silence Therapeutics
$9.95 /

+0.075 (+0.76%)

03/31/22 Chardan
Silence Therapeutics initiated with a Buy at Chardan
03/22/22 H.C. Wainwright
Silence Therapeutics price target lowered to $95 from $100 at H.C. Wainwright
Hot Stocks
T-Mobile exec sells $7.26M in common stock » 18:48
08/11/22
08/11
18:48
08/11/22
18:48
TMUS

T-Mobile

$143.57 /

-1.13 (-0.78%)

In a regulatory filing,…

In a regulatory filing, T-Mobile disclosed that its Technology President Nevilled Ray sold 50K shares of common stock on August 9th in a total transaction size of $7.26M.

ShowHide Related Items >><<
TMUS T-Mobile
$143.57 /

-1.13 (-0.78%)

TMUS T-Mobile
$143.57 /

-1.13 (-0.78%)

07/28/22 Cowen
T-Mobile price target raised to $187 from $179 at Cowen
07/28/22 Barclays
T-Mobile price target raised to $160 from $150 at Barclays
07/28/22 Scotiabank
T-Mobile upgraded to Outperform at Scotiabank on outgrowth over peers
07/28/22 Scotiabank
T-Mobile upgraded to Outperform from Sector Perform at Scotiabank
TMUS T-Mobile
$143.57 /

-1.13 (-0.78%)

  • 09
    Sep
TMUS T-Mobile
$143.57 /

-1.13 (-0.78%)

TMUS T-Mobile
$143.57 /

-1.13 (-0.78%)

TMUS T-Mobile
$143.57 /

-1.13 (-0.78%)

Hot Stocks
Algonquin Power declares Q3 common and preferred share dividends » 18:39
08/11/22
08/11
18:39
08/11/22
18:39
AQN

Algonquin Power

$14.46 /

-0.01 (-0.07%)

Algonquin Power has…

Algonquin Power has approved and declared the following common and preferred share dividends: 18.08c per common share, payable on October 14 to shareholders of record on September 29 for the period from July 1 to September 30; shareholders receiving dividends in cash can elect to receive the dividend in Canadian dollars in the amount of C$0.2312. C$0.32263 per preferred share, Series A, payable in cash on October 3 to preferred share, Series A holders of record on September 15 for the period from June 30 to, but excluding, September 30. C$0.31819 per preferred share, Series D, payable in cash on October 3 to preferred share, Series D holders of record on September 15 for the period from June 30 to, but excluding, September 30. . Plan Shares will be acquired by way of a treasury purchase at the average market price as defined in the Plan less a 3% discount.

ShowHide Related Items >><<
AQN Algonquin Power
$14.46 /

-0.01 (-0.07%)

AQN Algonquin Power
$14.46 /

-0.01 (-0.07%)

05/04/22 National Bank
Algonquin Power downgraded on rising bond yields at National Bank
05/04/22 National Bank
Algonquin Power downgraded to Sector Perform from Outperform at National Bank
11/10/21 BMO Capital
Algonquin Power upgraded to Outperform from Market Perform at BMO Capital
AQN Algonquin Power
$14.46 /

-0.01 (-0.07%)

On The Fly
Fly Intel: After-Hours Movers » 18:36
08/11/22
08/11
18:36
08/11/22
18:36
PAYO

Payoneer Global

$5.68 /

+0.045 (+0.80%)

, TOST

Toast

$18.12 /

-0.33 (-1.79%)

, LZ

LegalZoom

$11.11 /

-0.175 (-1.55%)

, JOBY

Joby Aviation

$6.17 /

+0.205 (+3.44%)

, PCT

PureCycle Technologies

$9.47 /

+0.215 (+2.32%)

, QTRX

Quanterix

$10.16 /

+1.6 (+18.69%)

, CODX

Co-Diagnostics

$6.44 /

-0.195 (-2.94%)

, OLO

Olo

$13.00 /

-0.235 (-1.78%)

, LAW

CS Disco

$28.96 /

+0.39 (+1.37%)

, SMSI

Smith Micro

$3.04 /

-0.055 (-1.78%)

, EXFY

Expensify

$24.41 /

+0.84 (+3.56%)

, ILMN

Illumina

$227.64 /

+0.44 (+0.19%)

, SST

System1

$8.69 /

+0.045 (+0.52%)

, FORG

ForgeRock

$22.24 /

-1.13 (-4.84%)

, PEAR

Pear Therapeutics

$2.25 /

+0.27 (+13.64%)

, CSSE

Chicken Soup for the Soul

$14.17 /

-0.59 (-4.00%)

, SMRT

SmartRent

$5.56 /

+0.015 (+0.27%)

, POSH

Poshmark

$12.91 /

+0.175 (+1.37%)

, MCW

Mister Car Wash

$12.00 /

-0.25 (-2.04%)

, BIOL

Biolase

$5.54 /

+0.15 (+2.78%)

, RIVN

Rivian Automotive

$38.91 /

+1.475 (+3.94%)

, CERT

Certara

$20.16 /

-0.19 (-0.93%)

Check out this evening's…

ShowHide Related Items >><<
TOST Toast
$18.12 /

-0.33 (-1.79%)

SST System1
$8.69 /

+0.045 (+0.52%)

SMSI Smith Micro
$3.04 /

-0.055 (-1.78%)

SMRT SmartRent
$5.56 /

+0.015 (+0.27%)

RIVN Rivian Automotive
$38.91 /

+1.475 (+3.94%)

QTRX Quanterix
$10.16 /

+1.6 (+18.69%)

POSH Poshmark
$12.91 /

+0.175 (+1.37%)

PEAR Pear Therapeutics
$2.25 /

+0.27 (+13.64%)

PCT PureCycle Technologies
$9.47 /

+0.215 (+2.32%)

PAYO Payoneer Global
$5.68 /

+0.045 (+0.80%)

OLO Olo
$13.00 /

-0.235 (-1.78%)

MCW Mister Car Wash
$12.00 /

-0.25 (-2.04%)

LZ LegalZoom
$11.11 /

-0.175 (-1.55%)

LAW CS Disco
$28.96 /

+0.39 (+1.37%)

JOBY Joby Aviation
$6.17 /

+0.205 (+3.44%)

ILMN Illumina
$227.64 /

+0.44 (+0.19%)

FORG ForgeRock
$22.24 /

-1.13 (-4.84%)

EXFY Expensify
$24.41 /

+0.84 (+3.56%)

CSSE Chicken Soup for the Soul
$14.17 /

-0.59 (-4.00%)

CODX Co-Diagnostics
$6.44 /

-0.195 (-2.94%)

CERT Certara
$20.16 /

-0.19 (-0.93%)

BIOL Biolase
$5.54 /

+0.15 (+2.78%)

PAYO Payoneer Global
$5.68 /

+0.045 (+0.80%)

07/14/22 Goldman Sachs
Payoneer Global upgraded to Buy from Neutral at Goldman Sachs
05/13/22 Northland
Payoneer Global price target lowered to $9 from $14 at Northland
05/13/22 Citi
Payoneer Global price target raised to $7.50 from $6.50 at Citi
03/04/22 Needham
Payoneer Global price target lowered to $7 from $13 at Needham
TOST Toast
$18.12 /

-0.33 (-1.79%)

05/17/22 Mizuho
Toast price target lowered to $18 from $19 at Mizuho
05/13/22 Needham
Toast price target lowered to $21 from $38 at Needham
05/13/22 Canaccord
Toast price target lowered to $25 from $34 at Canaccord
05/09/22 Mizuho
Toast price target lowered to $19 from $23 at Mizuho
LZ LegalZoom
$11.11 /

-0.175 (-1.55%)

07/28/22 Morgan Stanley
LegalZoom downgraded to Underweight on estimate risk at Morgan Stanley
07/28/22 Morgan Stanley
LegalZoom downgraded to Underweight from Equal Weight at Morgan Stanley
07/14/22 Morgan Stanley
LegalZoom price target lowered to $12 from $13 at Morgan Stanley
04/19/22 Citi
LegalZoom assumed with Buy from Neutral at Citi
JOBY Joby Aviation
$6.17 /

+0.205 (+3.44%)

07/27/22 Raymond James
Joby Aviation initiated with a Market Perform at Raymond James
04/28/22 JPMorgan
Joby Aviation initiated with a Neutral at JPMorgan
04/11/22 Deutsche Bank
Joby Aviation initiated with a Hold at Deutsche Bank
04/05/22 Cantor Fitzgerald
Joby Aviation initiated with an Overweight at Cantor Fitzgerald
PCT PureCycle Technologies
$9.47 /

+0.215 (+2.32%)

03/10/22 Craig-Hallum
PureCycle Technologies price target lowered to $18 from $26 at Craig-Hallum
03/10/22 Oppenheimer
PureCycle Technologies price target lowered to $16 from $28 at Oppenheimer
11/12/21 Craig-Hallum
PureCycle Technologies price target lowered to $26 from $48 at Craig-Hallum
09/23/21 Cowen
PureCycle Technologies initiated with an Outperform at Cowen
QTRX Quanterix
$10.16 /

+1.6 (+18.69%)

08/09/22 Cowen
Quanterix downgraded to Market Perform from Outperform at Cowen
08/09/22 SVB Securities
Quanterix downgraded to Market Perform from Outperform at SVB Securities
05/11/22 Cowen
Quanterix price target lowered to $38 from $60 at Cowen
03/15/22 BTIG
Quanterix price target lowered to $60 from $92 at BTIG
CODX Co-Diagnostics
$6.44 /

-0.195 (-2.94%)

05/16/22 H.C. Wainwright
Co-Diagnostics price target lowered to $12 from $15 at H.C. Wainwright
12/29/21 Sidoti
Sidoti starts Co-Diagnostics at Buy, sees opportunities opened by COVID-19 test
12/29/21 Sidoti
Co-Diagnostics initiated with a Buy at Sidoti
OLO Olo
$13.00 /

-0.235 (-1.78%)

07/18/22 Piper Sandler
Olo price target lowered to $13 from $14 at Piper Sandler
06/17/22 JPMorgan
Olo price target lowered to $21 from $26 at JPMorgan
02/24/22 Truist
Olo price target lowered to $25 from $45 at Truist
02/24/22 Piper Sandler
Olo price target lowered to $20 from $33 at Piper Sandler
LAW CS Disco
$28.96 /

+0.39 (+1.37%)

05/23/22 Jefferies
CS Disco price target lowered to $35 from $40 at Jefferies
05/13/22 Needham
CS Disco price target lowered to $35 from $50 at Needham
05/13/22 Cowen
CS Disco price target lowered to $35 from $45 at Cowen
05/13/22 Canaccord
CS Disco price target lowered to $35 from $45 at Canaccord
SMSI Smith Micro
$3.04 /

-0.055 (-1.78%)

03/11/22 Lake Street
Smith Micro price target lowered to $6 from $9 at Lake Street
03/11/22 B. Riley
Smith Micro price target lowered to $6.25 from $9.50 at B. Riley
03/11/22 Dawson James
Smith Micro price target lowered to $8.30 from $11.40 at Dawson James
01/03/22 B. Riley
iStar, Aspen Aerogels among B. Riley's top 25 stock picks for 2022
EXFY Expensify
$24.41 /

+0.84 (+3.56%)

08/11/22 Loop Capital
Expensify upgraded to Buy from Hold at Loop Capital
07/18/22 BofA
BofA upgrades 'category disruptor' Expensify to Buy with $25 target
07/18/22 BofA
Expensify upgraded to Buy from Neutral at BofA
06/15/22 JPMorgan
Expensify price target lowered to $30 from $47 at JPMorgan
ILMN Illumina
$227.64 /

+0.44 (+0.19%)

08/11/22 Piper Sandler
Illumina miss 'surprising' given backlog, says Piper Sandler
07/14/22 Canaccord
Illumina merger challenge not reflection of merits, says Canaccord
07/13/22 Piper Sandler
Illumina uncertainty over Grail continues with ruling, says Piper Sandler
07/13/22 Barclays
Illumina downgraded to Underweight from Equal Weight at Barclays
SST System1
$8.69 /

+0.045 (+0.52%)

07/11/22 BofA
BofA starts System1 at Buy with $12 price target
07/11/22 BofA
System1 initiated with a Buy at BofA
04/26/22 Evercore ISI
System1 initiated with an In Line at Evercore ISI
04/06/22 DA Davidson
System1 price target raised to $26 from $23 at DA Davidson
FORG ForgeRock
$22.24 /

-1.13 (-4.84%)

07/13/22 Piper Sandler
ForgeRock price target raised to $25 from $24 at Piper Sandler
06/22/22 JPMorgan
ForgeRock price target lowered to $30 from $36 at JPMorgan
05/12/22 Deutsche Bank
ForgeRock price target lowered to $15 from $16 at Deutsche Bank
05/12/22 Mizuho
ForgeRock price target lowered to $24 from $32 at Mizuho
PEAR Pear Therapeutics
$2.25 /

+0.27 (+13.64%)

06/24/22 BTIG
Pear Therapeutics price target lowered to $11 from $12 at BTIG
05/24/22 Cowen
Pear Therapeutics revenues raised on strong Rx growth, says Cowen
05/17/22 Chardan
Pear Therapeutics price target lowered to $13 from $16 at Chardan
05/17/22 Citi
Pear Therapeutics price target raised to $11 from $10 at Citi
CSSE Chicken Soup for the Soul
$14.17 /

-0.59 (-4.00%)

07/12/22 B. Riley
Chicken Soup sees positive free cash flow by year-end, says B. Riley
06/14/22 DA Davidson
DA Davidson likes Chicken Soup for the Soul amid strong box office, Redbox deal
05/27/22 B. Riley
Redbox downgraded to Sell from Neutral at B. Riley
05/17/22 Guggenheim
Chicken Soup for the Soul resumed with a Buy at Guggenheim
SMRT SmartRent
$5.56 /

+0.015 (+0.27%)

07/22/22 Cantor Fitzgerald
SmartRent assumed with an Overweight at Cantor Fitzgerald
07/19/22 Keefe Bruyette
Bain Capital sold 5% of stake in SmartRent, says Keefe Bruyette
05/25/22 Compass Point
Compass Point starts SmartRent at Buy, sees 'exponential growth potential'
05/25/22 Compass Point
SmartRent initiated with a Buy at Compass Point
POSH Poshmark
$12.91 /

+0.175 (+1.37%)

07/27/22 MKM Partners
MKM assumes Poshmark with Neutral rating, cites near-term profitability concerns
07/27/22 MKM Partners
Poshmark assumed with a Neutral at MKM Partners
06/29/22 Raymond James
Poshmark downgraded to Market Perform from Outperform at Raymond James
06/28/22 Stifel
Poshmark price target raised to $13 from $12 at Stifel
MCW Mister Car Wash
$12.00 /

-0.25 (-2.04%)

06/27/22 Goldman Sachs
Mister Car Wash downgraded to Sell from Neutral at Goldman Sachs
05/13/22 BMO Capital
Mister Car Wash price target lowered to $18 from $23 at BMO Capital
05/13/22 Piper Sandler
Mister Car Wash price target lowered to $13 from $18 at Piper Sandler
03/25/22 BMO Capital
Mister Car Wash price target lowered to $23 from $25 at BMO Capital
BIOL Biolase
$5.54 /

+0.15 (+2.78%)

05/20/22 Lake Street
Biolase initiated with a Buy at Lake Street
08/19/21 Ascendiant
Biolase price target raised to $3 from $2 at Ascendiant
RIVN Rivian Automotive
$38.91 /

+1.475 (+3.94%)

07/18/22 Deutsche Bank
Rivian Automotive price target lowered to $46 from $69 at Deutsche Bank
07/13/22 Canaccord
Rivian Automotive initiated with a Buy at Canaccord
07/08/22 Wedbush
Wedbush ups Rivian target, says story 'starting to turn the corner'
07/06/22 RBC Capital
Rivian Automotive's Q2 deliveries stronger than expected, says RBC Capital
CERT Certara
$20.16 /

-0.19 (-0.93%)

08/10/22 Piper Sandler
Certara price target lowered to $25 from $28 at Piper Sandler
07/15/22 SVB Securities
Certara initiated with an Outperform at SVB Securities (earlier)
07/13/22 Barclays
Certara price target lowered to $24 from $25 at Barclays
07/01/22 Piper Sandler
Certara initiated with an Overweight at Piper Sandler
TOST Toast
$18.12 /

-0.33 (-1.79%)

SST System1
$8.69 /

+0.045 (+0.52%)

SMSI Smith Micro
$3.04 /

-0.055 (-1.78%)

SMRT SmartRent
$5.56 /

+0.015 (+0.27%)

RIVN Rivian Automotive
$38.91 /

+1.475 (+3.94%)

QTRX Quanterix
$10.16 /

+1.6 (+18.69%)

POSH Poshmark
$12.91 /

+0.175 (+1.37%)

PEAR Pear Therapeutics
$2.25 /

+0.27 (+13.64%)

PAYO Payoneer Global
$5.68 /

+0.045 (+0.80%)

OLO Olo
$13.00 /

-0.235 (-1.78%)

MCW Mister Car Wash
$12.00 /

-0.25 (-2.04%)

LZ LegalZoom
$11.11 /

-0.175 (-1.55%)

LAW CS Disco
$28.96 /

+0.39 (+1.37%)

JOBY Joby Aviation
$6.17 /

+0.205 (+3.44%)

ILMN Illumina
$227.64 /

+0.44 (+0.19%)

FORG ForgeRock
$22.24 /

-1.13 (-4.84%)

EXFY Expensify
$24.41 /

+0.84 (+3.56%)

CSSE Chicken Soup for the Soul
$14.17 /

-0.59 (-4.00%)

CODX Co-Diagnostics
$6.44 /

-0.195 (-2.94%)

CERT Certara
$20.16 /

-0.19 (-0.93%)

BIOL Biolase
$5.54 /

+0.15 (+2.78%)

  • 12
    Aug
  • 18
    Nov
  • 10
    Nov
  • 10
    Nov
  • 22
    Sep
  • 15
    Sep
  • 16
    Sep
  • 09
    Sep
  • 24
    Aug
RIVN Rivian Automotive
$38.91 /

+1.475 (+3.94%)

POSH Poshmark
$12.91 /

+0.175 (+1.37%)

JOBY Joby Aviation
$6.17 /

+0.205 (+3.44%)

ILMN Illumina
$227.64 /

+0.44 (+0.19%)

TOST Toast
$18.12 /

-0.33 (-1.79%)

SST System1
$8.69 /

+0.045 (+0.52%)

SMRT SmartRent
$5.56 /

+0.015 (+0.27%)

RIVN Rivian Automotive
$38.91 /

+1.475 (+3.94%)

QTRX Quanterix
$10.16 /

+1.6 (+18.69%)

POSH Poshmark
$12.91 /

+0.175 (+1.37%)

PEAR Pear Therapeutics
$2.25 /

+0.27 (+13.64%)

PCT PureCycle Technologies
$9.47 /

+0.215 (+2.32%)

PAYO Payoneer Global
$5.68 /

+0.045 (+0.80%)

MCW Mister Car Wash
$12.00 /

-0.25 (-2.04%)

LZ LegalZoom
$11.11 /

-0.175 (-1.55%)

JOBY Joby Aviation
$6.17 /

+0.205 (+3.44%)

ILMN Illumina
$227.64 /

+0.44 (+0.19%)

FORG ForgeRock
$22.24 /

-1.13 (-4.84%)

EXFY Expensify
$24.41 /

+0.84 (+3.56%)

CSSE Chicken Soup for the Soul
$14.17 /

-0.59 (-4.00%)

CODX Co-Diagnostics
$6.44 /

-0.195 (-2.94%)

TOST Toast
$18.12 /

-0.33 (-1.79%)

SST System1
$8.69 /

+0.045 (+0.52%)

RIVN Rivian Automotive
$38.91 /

+1.475 (+3.94%)

POSH Poshmark
$12.91 /

+0.175 (+1.37%)

PEAR Pear Therapeutics
$2.25 /

+0.27 (+13.64%)

PCT PureCycle Technologies
$9.47 /

+0.215 (+2.32%)

PAYO Payoneer Global
$5.68 /

+0.045 (+0.80%)

JOBY Joby Aviation
$6.17 /

+0.205 (+3.44%)

ILMN Illumina
$227.64 /

+0.44 (+0.19%)

EXFY Expensify
$24.41 /

+0.84 (+3.56%)

CSSE Chicken Soup for the Soul
$14.17 /

-0.59 (-4.00%)

CODX Co-Diagnostics
$6.44 /

-0.195 (-2.94%)

Hot Stocks
Agios announces publication of Phase 2 PYRUKYND data in The Lancet » 18:35
08/11/22
08/11
18:35
08/11/22
18:35
AGIO

Agios Pharmaceuticals

$25.98 /

-2.2499 (-7.97%)

Agios Pharmaceuticals…

Agios Pharmaceuticals announced that data from the core period of the open-label, Phase 2 study of PYRUKYND in adults with non-transfusion-dependent alpha- or beta-thalassemia were published on August 11, 2022, in The Lancet. Data from this study were previously presented at the 2021 European Hematology Association Annual Congress. PYRUKYND is a first-in-class, investigational, oral, small molecule allosteric activator of wild-type and a variety of mutated pyruvate kinase enzymes. "Consistent with previously reported findings, the data reported today underscore the potential of PK activation to improve hallmarks of alpha- and beta-thalassemia, including hemolysis and ineffective erythropoiesis," said Kevin Kuo, M.D., hematologist at University of Toronto, Toronto General Hospital, and an investigator in the study. "Thalassemia is a rare, debilitating lifelong blood disorder characterized by severe complications, with no treatment options for those with alpha-thalassemia and limited options for those with beta-thalassemia. These data demonstrate the potential clinical benefits of mitapivat for a broad spectrum of thalassemia patients and support its continued investigation in pivotal trials."

ShowHide Related Items >><<
AGIO Agios Pharmaceuticals
$25.98 /

-2.2499 (-7.97%)

AGIO Agios Pharmaceuticals
$25.98 /

-2.2499 (-7.97%)

07/27/22 SVB Securities
Agios Pharmaceuticals upgraded to Outperform from Market Perform at SVB Securities
02/25/22 RBC Capital
Agios Pharmaceuticals price target raised to $67 from $61 at RBC Capital
02/24/22 H.C. Wainwright
Agios Pharmaceuticals price target lowered to $96 from $98 at H.C. Wainwright
02/18/22 H.C. Wainwright
Agios Pharmaceuticals price target raised to $98 from $95 at H.C. Wainwright
AGIO Agios Pharmaceuticals
$25.98 /

-2.2499 (-7.97%)

Hot Stocks
Taro Pharmaceutical issues voluntary recall of taro-zoledronic acid injection » 18:19
08/11/22
08/11
18:19
08/11/22
18:19
TARO

Taro Pharmaceutical

$34.70 /

-0.2198 (-0.63%)

Taro Pharmaceuticals has…

Taro Pharmaceuticals has initiated a voluntary Type 1 recall to the patient level on six lots of Taro-Zoledronic Acid Injection, 5 mg/100 mL in 100 mL vials. The reason for the recall is that product from these lots may contain particulate matter over the specified requirements. This recall is being conducted with the knowledge of Health Canada. The presence of foreign particulate matter in vials of the affected lots could potentially cause unintended adverse events. Taro has received no reports of serious adverse events associated with this product. Taro-Zoledronic Acid Injection, 5 mg/100 mL is used to increase bone mineral density, to treat and prevent osteoporosis as well as to treat Paget's disease, a condition that causes bone deformities.

ShowHide Related Items >><<
TARO Taro Pharmaceutical
$34.70 /

-0.2198 (-0.63%)

TARO Taro Pharmaceutical
$34.70 /

-0.2198 (-0.63%)

01/31/22 H.C. Wainwright
Taro Pharmaceutical price target lowered to $73 from $75 at H.C. Wainwright
01/18/22 H.C. Wainwright
Taro Pharmaceutical price target lowered to $75 from $82 at H.C. Wainwright
TARO Taro Pharmaceutical
$34.70 /

-0.2198 (-0.63%)

Hot Stocks
Quanterix director buys $100K in common stock » 18:19
08/11/22
08/11
18:19
08/11/22
18:19
QTRX

Quanterix

$10.16 /

+1.6 (+18.69%)

In a regulatory filing,…

In a regulatory filing, Quanterix director Sarah Hlavinka disclosed the purchase of 10.1K common shares of the company on August 11 at a price of $9.89 per share. Shares of Quanterix rose 18.7% today following insider buying activity yesterday evening and are up another 6.2% afterhours.

ShowHide Related Items >><<
QTRX Quanterix
$10.16 /

+1.6 (+18.69%)

QTRX Quanterix
$10.16 /

+1.6 (+18.69%)

08/09/22 Cowen
Quanterix downgraded to Market Perform from Outperform at Cowen
08/09/22 SVB Securities
Quanterix downgraded to Market Perform from Outperform at SVB Securities
05/11/22 Cowen
Quanterix price target lowered to $38 from $60 at Cowen
03/15/22 BTIG
Quanterix price target lowered to $60 from $92 at BTIG
QTRX Quanterix
$10.16 /

+1.6 (+18.69%)

QTRX Quanterix
$10.16 /

+1.6 (+18.69%)

Periodicals
HSBC overstated risks of Asia unit spinoff, Reuters reports » 18:17
08/11/22
08/11
18:17
08/11/22
18:17
HSBC

HSBC

$33.50 /

+0.23 (+0.69%)

HSBC oversold the risks…

HSBC oversold the risks of spinning off its Asia business when it spurned such a proposal by stakeholder Ping An, Reuters' Selena Li, Lawrence White, and Anshuman Daga report, citing a source familiar with the Chinese insurer's thinking. The move could unlock up to $35B in value for the bank, the authors say, citing the source. Reference Link

ShowHide Related Items >><<
HSBC HSBC
$33.50 /

+0.23 (+0.69%)

HSBC HSBC
$33.50 /

+0.23 (+0.69%)

08/08/22 RBC Capital
HSBC price target raised to 650 GBp from 590 GBp at RBC Capital
08/03/22 Goldman Sachs
HSBC downgraded to Neutral from Buy at Goldman Sachs
08/03/22 Berenberg
HSBC price target raised to 625 GBp from 560 GBp at Berenberg
08/03/22 UBS
HSBC price target raised to 680 GBp from 635 GBp at UBS
HSBC HSBC
$33.50 /

+0.23 (+0.69%)

HSBC HSBC
$33.50 /

+0.23 (+0.69%)

HSBC HSBC
$33.50 /

+0.23 (+0.69%)

HSBC HSBC
$33.50 /

+0.23 (+0.69%)

Hot Stocks
Court affirms ruling barring Minerva from challenging Hologic's patent rights » 18:13
08/11/22
08/11
18:13
08/11/22
18:13
HOLX

Hologic

$72.02 /

-0.2 (-0.28%)

, NERV

Minerva

$3.35 /

-0.12 (-3.46%)

Hologic (HOLX) announced…

Hologic (HOLX) announced that the U.S. Court of Appeals for the Federal Circuit has affirmed a 2018 district court ruling that barred Minerva (NERV) from challenging the validity of the patent rights it assigned to Hologic. "We are pleased that the U.S. Court of Appeals has once again ruled in our favor. This important decision confirms that good faith and fair dealing apply to transactions involving patents and provides greater certainty for companies like Hologic who acquire innovative technologies in order to provide physicians and their patients with the latest solutions," said Essex Mitchell, President of Hologic's GYN Surgical Solutions Division. In 2015, Hologic sued Minerva alleging that the company's endometrial ablation system infringes patents acquired by Hologic through its 2004 purchase of Novacept, the developer of the NovaSure endometrial ablation system for abnormal uterine bleeding. The suit alleged that four years after Hologic's acquisition of Novacept, a former Novacept executive founded Minerva and developed and commercialized an endometrial ablation device using the patented technology that was acquired by Hologic in the Novacept transaction. In 2018, a Delaware district court found Minerva liable for patent infringement and barred the company's invalidity defenses under assignor estoppel. A jury awarded Hologic $4.8M in damages for Minerva's infringement. This decision by the U.S. Court of Appeals is the latest decision in Hologic's favor on this matter. In 2019, the Federal Circuit affirmed the district court ruling on infringement and assignor estoppel. In 2021, the U.S. Supreme Court clarified the scope of assignor estoppel and, on remand, the Federal Circuit again ruled in Hologic's favor, holding that Minerva's invalidity challenge contradicted multiple representations made by the Novacept executive, including in assigning the patent. With the Federal Circuit decision, Minerva must now pay Hologic more than $7M in damages, which includes the $4.8M in damages originally awarded plus post-trial damages and interest.

ShowHide Related Items >><<
NERV Minerva
$3.35 /

-0.12 (-3.46%)

HOLX Hologic
$72.02 /

-0.2 (-0.28%)

HOLX Hologic
$72.02 /

-0.2 (-0.28%)

07/22/22 Evercore ISI
Intuitive Surgical price target lowered to $175 from $210 at Evercore ISI
07/20/22 UBS
Hologic initiated with a Neutral at UBS
07/20/22 BofA
BofA cuts Hologic to Neutral amid difficult macro, ongoing supply chain issues
07/20/22 BofA
Hologic downgraded to Neutral from Buy at BofA
NERV Minerva
$3.35 /

-0.12 (-3.46%)

03/04/22 H.C. Wainwright
Minerva price target lowered to $5 from $10 at H.C. Wainwright
NERV Minerva
$3.35 /

-0.12 (-3.46%)

HOLX Hologic
$72.02 /

-0.2 (-0.28%)

HOLX Hologic
$72.02 /

-0.2 (-0.28%)

Hot Stocks
Teens are leaving Facebook, YouTube used by 95% of teens, Pew Research says » 18:01
08/11/22
08/11
18:01
08/11/22
18:01
META

Meta Platforms

$177.46 /

-0.88 (-0.49%)

, TWTR

Twitter

$43.95 /

-0.47 (-1.06%)

, SNAP

Snap

$11.11 /

+0.54 (+5.11%)

, GOOG

Alphabet

$119.84 /

-0.8 (-0.66%)

, GOOGL

Alphabet

$118.90 /

-0.78 (-0.65%)

"The landscape of…

"The landscape of social media is ever-changing, especially among teens who often are on the leading edge of this space. A new Pew Research Center survey of American teenagers ages 13 to 17 finds TikTok has rocketed in popularity since its North American debut several years ago and now is a top social media platform for teens among the platforms covered in this survey. Some 67% of teens say they ever use TikTok, with 16% of all teens saying they use it almost constantly. Meanwhile, the share of teens who say they use Facebook, a dominant social media platform among teens in the Center's 2014-15 survey, has plummeted from 71% then to 32% today. YouTube (GOOG) tops the 2022 teen online landscape among the platforms covered in the Center's new survey, as it is used by 95% of teens. TikTok is next on the list of platforms that were asked about in this survey,67%, followed by Instagram and Snapchat (SNAP), which are both used by about six-in-ten teens. After those platforms come Facebook (META) with 32% and smaller shares who use Twitter (TWTR), Twitch, WhatsApp, Reddit and Tumblr,"wrote Emily Vogels, Risa Gelles-Watnick and Navid Massarat for Pew Research. Reference Link

ShowHide Related Items >><<
TWTR Twitter
$43.95 /

-0.47 (-1.06%)

SNAP Snap
$11.11 /

+0.54 (+5.11%)

META Meta Platforms
$177.46 /

-0.88 (-0.49%)

GOOG Alphabet
$119.84 /

-0.8 (-0.66%)

META Meta Platforms
$177.46 /

-0.88 (-0.49%)

08/11/22 Loop Capital
Loop Capital has 'stronger conviction' in Enovix after 'customer milestones'
08/10/22 BofA
Meta Platforms added to US 1 List; Alphabet removed at BofA
08/09/22 Stifel
Unity price target raised to $60 at Stifel after AppLovin proposal
08/05/22 Needham
Meta Platforms outlook made worse by Apple's AdTech platform, says Needham
TWTR Twitter
$43.95 /

-0.47 (-1.06%)

08/10/22 Gordon Haskett
Tesla sale shows Musk knows must come up with Twitter money, says Gordon Haskett
08/10/22 Wedbush
Twitter price target raised to $50 from $30 at Wedbush
08/05/22 Susquehanna
Susquehanna downgrades Twitter on 'uncertainty and disruption' from takeover
08/05/22 Susquehanna
Twitter downgraded to Neutral from Positive at Susquehanna
SNAP Snap
$11.11 /

+0.54 (+5.11%)

07/27/22 Jefferies
Alphabet price target lowered to $130 from $155 at Jefferies
07/27/22 Morgan Stanley
Alphabet price target raised to $145 from $140 at Morgan Stanley
07/25/22 Argus
Snap downgraded to Hold from Buy at Argus
07/25/22 MoffettNathanson
Snap downgraded to Market Perform at MoffettNathanson (Friday)
GOOG Alphabet
$119.84 /

-0.8 (-0.66%)

08/10/22 Oppenheimer
Trade Desk price target raised to $78 from $60 at Oppenheimer
08/03/22 Tigress Financial
Alphabet price target raised to $186 from $183 at Tigress Financial
07/27/22 Truist
Chrome cookie phase-out delay positive for Criteo, says Truist
GOOGL Alphabet
$118.90 /

-0.78 (-0.65%)

08/10/22 Needham
Trade Desk price target raised to $65 from $55 at Needham
TWTR Twitter
$43.95 /

-0.47 (-1.06%)

SNAP Snap
$11.11 /

+0.54 (+5.11%)

META Meta Platforms
$177.46 /

-0.88 (-0.49%)

GOOG Alphabet
$119.84 /

-0.8 (-0.66%)

TWTR Twitter
$43.95 /

-0.47 (-1.06%)

SNAP Snap
$11.11 /

+0.54 (+5.11%)

META Meta Platforms
$177.46 /

-0.88 (-0.49%)

GOOG Alphabet
$119.84 /

-0.8 (-0.66%)

TWTR Twitter
$43.95 /

-0.47 (-1.06%)

SNAP Snap
$11.11 /

+0.54 (+5.11%)

META Meta Platforms
$177.46 /

-0.88 (-0.49%)

GOOG Alphabet
$119.84 /

-0.8 (-0.66%)

TWTR Twitter
$43.95 /

-0.47 (-1.06%)

SNAP Snap
$11.11 /

+0.54 (+5.11%)

META Meta Platforms
$177.46 /

-0.88 (-0.49%)

GOOGL Alphabet
$118.90 /

-0.78 (-0.65%)

GOOG Alphabet
$119.84 /

-0.8 (-0.66%)

Upgrade
Swire Pacific upgraded to Buy from Neutral at Goldman Sachs » 17:56
08/11/22
08/11
17:56
08/11/22
17:56
SWRAY

Swire Pacific

$6.32 /

+0.54 (+9.34%)

Goldman Sachs analyst…

Goldman Sachs analyst Simon Cheung upgraded Swire Pacific to Buy from Neutral with a price target of HK$79, up from HK$66. The group may continue to see uncertainties for its various businesses in near term amid viral outbreaks and cost inflation, but the worst appears to be over for the company with signs of recovery ahead, the analyst tells investors in a research note.

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.